Contact Information
David Horne, Ph.D.
  • Vice Provost and Associate Director, Beckman Research Institute
  • Chair and Professor, Molecular Medicine
  • Dean of Faculty Affairs
  • Director, Synthetic and Biopolymer Chemistry Core
  • Co-director, Drug Discovery and Structural Biology (DDSB) Core

Biography

Biography

David Horne, Ph.D. is vice provost and associate director of Beckman Research Institute and dean of faculty affairs. In this role, he oversees the Irell and Manella Graduate School of Biological Sciences, the Postdoctoral Training Office, International Research Programs, and the Office of Faculty Affairs. Horne and Steven T. Rosen, M.D, Provost and Chief Scientific Officer are institutional leaders in all aspects of academic scientific and medical education, shaping the scientific and educational vision for City of Hope. As associate director, he assists Dr. Rosen in his responsibilities as Beckman Research Institute director.
 
Horne is well-known for his scientific and research expertise, as well as his ability to build strong relationships with faculty and leaders across our organization and at partnering institutions. He has held numerous leadership positions since first joining the Beckman Research Institute in 2006, including his most recent role as Interim Director. Horne’s professional experience is complemented by impressive academic achievements in the area of medicinal chemistry and drug development. Horne holds a Ph.D. in chemistry from the Massachusetts Institute of Technology and B.S. in chemistry from UCLA. He was a National Institutes of Health postdoctoral fellow at the California Institute of Technology as well as a Beckman Young Investigator and National Science Young Investigator Awardee.
 

Professional Experience

  • 2014 - present, Deputy Director for Research, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2012 - present, Interim Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2011 Associate Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2011 Co-Director, Drug Discovery and Structural Biology (DDSB) Core, Beckman Research Institute of City of Hope, Duarte, CA
  • 2009 - present, Co-leader, Developmental Cancer Therapeutics Program, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2008 - present, Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2007 - 2008, Associate Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 - present, Director, Synthetic and Biopolymer Chemistry Core Facility, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 Professor, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2004 Professor of Chemistry, Oregon State University, OR
  • 1998 Associate Professor of Chemistry, Oregon State University, OR
  • 1997 Associate Professor of Chemistry, Columbia University, New York City, NY
  • 1993 Adjunct Professor, Department of Biology, Columbia University, New York City, NY
  • 1992 Assistant Professor of Chemistry, Columbia University, New York City, NY
  • 1989 NIH Postdoctoral Fellow, California Institute of Technology, Pasadena, CA

Education

 
Education/Training
 
  • 1989 NIH Postdoctoral Fellow, California Institite of Technology, Pasadena, CA
  • 1988 Massachusetts Institute of Technology, Ph.D., Chemistry
  • 1984 University of California, Los Angeles, M.S., Chemistry
  • 1983 University of California, Los Angeles, B.S., Chemistry
 

Honors/Awards

 
Awards
 
  • 2004 Olaf Boedtker Faculty Inspiration Award, College of Science, Oregon State University
  • 2002 Harris Teaching Award, Department of Chemistry, Oregon State University
  • 2001 Lloyd Carter Teaching Award, College of Science, Oregon State University
  • 1996 Great Teacher Award, Honorable Mention, Columbia University
  • 1995 National Science Foundation Young Investigator Award
  • 1993 Becton-Dickson Fellow
  • 1992 Beckman Young Investigator Award
  • 1989 National Institutes of Health Postdoctoral Fellow

Honors

  • 2011 Member, Scientific Advisory Board, Arnold and Mabel Beckman Foundation
 

Memberships


  • 2013 Chair, NIH NCATS, TRND Study Section
  • 2013 Ad hoc Member, SBIR ((Biological Chemistry, Biophysics, and Drug Discovery) Study Section
  • 2009 Ad hoc Member, National Institutes of Health F32 Study Section
  • 2007 Ad hoc Member, National Institutes of Health K99-R00 Pathway to Independence Study Section
  • 2006 Ad hoc Member, National Institutes of Health SBCA Study Section
  • 2001 - 2006, Permanent Member, National Institutes of Health MCHA/SBCA Study Section
  • 2000 Ad hoc Member, National Institutes of Health MCHA Study Section
  • 1998 Ad hoc Member, National Institutes of Health MCHA Study Section
  • 1997 Ad hoc Member, National Institutes of Health MCHA Study Section

Publications


Representative Publications
  • “Tricyclic analogues of epidithiodioxopiperazine alkaloids with promising in vitro and in vivo antitumor activity” Baumann, M.; Dieskau, A. P.; Loertscher, B. M.; Walton, M. C.; Nam, S.; Xie, J.; Horne, D.; Overman, L. E. Chem. Sci. 2015, 6, 4451-4457.
  • “2'-Hydroxyflavanone: A promising molecule for kidney cancer prevention” Singhal, S. S.; Singhal, J.; Figarola, J. L.; Riggs, A.; Horne, D.; Awasthi, S. Biochem. Pharmacol. 2015, (pages ahead of print).
    “LIP76 Targeted Therapy for Kidney Cancer” Singhal, S. S.; Singhal, J.; Figarola, J.; Horne, D.; Awasthi, S. Pharmaceut. Res. 2015, (pages ahead of print)
  • “Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer”  Wen, W.; Wu, J.; Liu, L.; Tian, Y.; Buettner, R.; Hsieh, M.-Y.; Horne, D.; Dellinger, T. H.; Han, E. S.; Jove, R.; Yim, J. H. Mol Cancer, 2015, 14, 1-21.
  • “Enantioselective Synthesis of α-Secondary and α-Tertiary Piperazin-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation” Korch, K. M.; Eidamshaus, C.; Behenna, D. C.; Nam, S.; Horne, D.; Stoltz, B. M. Angew. Chem. Int. Ed. 2015, 54, 179-183.
  • "Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer" Wen, W.; Liang, W.; Wu, J.; Kowolik, C. M.; Buettner, R.; Scuto, A.; Hsieh, M.-Y.; Hong, H.; Brown, C.  E.; Forman, S. J.; Horne, D.; Morgan, R.; Wakabayashi, M.; Dellinger, T. H.; Han, E. S.; Yim, J. H.; Jove, R.  Mol. Cancer Ther. 2014, 13(12), 3037-3048.
  • "Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells" Wang, Y.; Han, E.; Xing, Q.; Yan, J.; Arrington, A.; Wang, C.; Tully, D.; Kowolik, C. M.; Lu, D. M.; Frankel, P. H.; Zhai, J.; Wen, W.; Horne, D.; Yip, M. L. R.; Yim, J. H. Cancer Lett. 2015, 358, 170-179.
  • "Facile preparation of a thiol-reactive 18F-labeling agent and synthesis of 18F-DEG-VS-NT for PET imaging of a neurotensin receptor-positive tumor" Wu, Z.; Li, L.; Liu, S.; Yakushijin, F.; Yakushijin, K.; Horne, D.; Conti, P. S.; Li, Z.; Kandeel, F.; Shively, J. E. J. Nucl. Med. 2014, 55, 1178-1184.
  • “A Novel Berbamine Derivative Inhibits Cell Viability and Induces Apoptosis in Cancer Stem-Like Cells of Human Glioblastoma, via Up-Regulation of miRNA-4284 and JNK/AP-1 Signaling” Fan, Y.; Nam S.; Zhao R.; Ma Y.; Xie J.; Horne D. A.; Brown C. E.; Starr R.; Malkas L. H; Jove R.; Hickey R. J. PLoS One 2014, 9, e100708.
  • “Photocleavable Dimerizer for the Rapid Reversal of Molecular Trap Antagonists” Shubbir, A.; Xie, J.; Horne, D.; Williams, J. C. J. Biol. Chem. 2014, 289, 4546-52.
  • “Identification and Grafting of a Unique Peptide-Binding Site in the Fab Framework of Monoclonal Antibodies” Donaldson, J. M.; Zer, C.; Avery, K. N.; Bzymek, K. P.; Horne, D. A.; Williams, J. C. Proc. Natl. Acad. Sci. 2013, 110, 17456-61.
  • “General Approach for Preparing Epidithiodioxopiperazines from Trioxopiperazine Precursors: Enantioselective Total Syntheses of (+)- and (-)-Gliocladine C, (+)-Leptosin D, (+)-T988C, (+)-Bionectin A, and (+)-Gliocladin A” DeLorbe, J. E.; Horne, D.; Jove, R.; Mennen, S. M.; Nam, S.; Zhang, F.-L.; Overman, L. E. J. Am. Chem. Soc. 2013, 135, 4117-4128.
  • “A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance” Zhou, B.; Su, L.; Hu, S.; Hu, W.; Yip, M. L. R.; Wu, J.; Gaur, S.; Smith, D. L.; Yuan, Y.-C.; Synold, T. W.; Horne, D.; Yen, Y. Cancer Res 2013, 73, 6484-6493.
  • “Amphidinolide B: Total Synthesis, Structural Investigation, and Biological Evaluation” Lu, L.; Zhang, W.; Nam, S.; Horne, D. A.; Jove, R.; Carter, R. G. J. Org. Chem. 2013, 78, 2213-2247..
 

Patents

 
Representative Patents
 
  • Non-provisional patent application (USA) 14/083,938, “Photocleavable Linker” Filed: 11/19/2013.
  • PCT Application/US2013/066252 “ETP Derivatives” Filed: 10/22/2013.
  • Non-provisional patent application (USA) 13/953,013, “Novel Modulators and Development of Adipocyte and Cancer Cells” Filed: 7/29/2013.
  • Non-provisional application (USA) 13/776,374, “Isatin Derivatives, Pharmaceutical Compositions Thereof, and Methods of Use Thereof” Filed: 2/25/2013.
  • PCT Application/US2013/24490, “Synthesis of COH 29” Filed: 2/1/2013.
  • PCT Application/US2012/32938, “Meditopes and Meditope-Binding Antibodies and Uses Thereof” Filed: 4/10/2012.
  • Non-provisional patent application (USA) “Multi-Valent Poly-SUMO Chain Inhibitor and Methods of Use” 13/401,642, Filed: 2/21/2012.
  • PCT Application/US2012/23034, “Novel Modulators of Development of Adipocyte And Cancer Cells” Filed: 1/27/2012.
  • Non-provisional patent application (USA) “Humanized Lewis-Y Specific Antibody-Based Delivery of Dicer Substrate siRNA (D-siRNA) Against STAT3” 61/454,458, Filed: 3/18/2011.
  • Non-provisional patent application (USA) “Berbamine Derivatives” 12/783,535, Filed: 5/19/2010.
  • US Patent 8,163,783 “Ribonuclease Reductase Inhibitors and Methods of use” Issued: 4/25/2011.
  • US Patent 7,956,076 “Ribonuclease Reductase Inhibitors and Methods of use” Issued: 4/8/2009.
  • US Patent 7,615,638 “Synthesis of Grossularines-1 and Analogs Thereof and Method of Use” Issued: 4/30/2007.
  • U.S. Patent 6,841,658 “Methods for Making Bis-Heterocyclic Alkaloids” Issued: 1/11/2005.
  • U.S. Patent 6,211,361 “Method for Making Debromohymenialdisine and Analogs Thereof” Issued: 4/3/01.
  • U.S. Patent 6,197,954. “Intermediates for the Synthesis of Debromohymenialdisine and Processes Thereof” Issued: 3/6/01.
  • U.S. Patent 6,103,899. “Bicyclic Aminoimidazoles” Issued: 8/15/00.
  • PCT Int. Appl. (1998), WO 9809935. “Intermediates for the Synthesis of Vitamin D and Steroid Derivatives and Processes for Preparation Thereof” Issued: 3/12/98.
  • U.S. Patent 5,834,609. “Bicyclic Aminoimidazoles” Issued: 6/10/98.

Locations


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010